

# 21-Gene Recurrence Score Adds Significant Value for Grade 3 Breast Cancers: Results From a National Cohort

J. Bryan Iorgulescu, MD<sup>1,2,3</sup>; Rachel A. Freedman, MD, MPH<sup>2,3</sup>; Susan C. Lester, MD, PhD<sup>1,2</sup>; Elizabeth A. Mittendorf, MD, PhD<sup>1,2</sup>; and Jane E. Brock, MBBS, PhD<sup>1,2</sup>

**PURPOSE** The 21-gene recurrence score (RS) is used to identify patients with hormone receptor–positive early-stage breast cancer who may benefit from the addition of chemotherapy to endocrine therapy. We hypothesized that many women with poor prognostic histopathologic grade 3 disease may be offered chemotherapy irrespective of RS results, of whom a subset may not benefit from adjuvant chemotherapy.

**PATIENTS AND METHODS** A total of 30,864 women in the National Cancer Database were diagnosed with pT1c to pT2, pN0 to pN1, grade 3 estrogen receptor–positive, human epidermal growth factor receptor 2–negative invasive breast carcinoma from 2010 to 2015. RS was stratified as low (less than 18), intermediate (18 to 30), and high (31 or more). Overall survival by RS was evaluated by Kaplan-Meier, log-rank, and multivariable proportional hazards, with adjustment for relevant clinical and demographic variables.

**RESULTS** RS testing in grade 3 cancers increased between 2010 and 2015 (pN0, 53% to 72%; pN1, 16% to 36%). Among the 13,558 women with pN0 and the 2,840 with pN1 disease with RS testing, 27.1% and 30.0%, respectively, had low scores (less than 18). The 5-year overall survival rate for patients with a high RS, but not low RS, was significantly higher with chemotherapy (v no chemotherapy; absolute differences: high RS pN0 = 12.2% and pN1 = 25.5%, both  $P < .001$ ; low RS pN0 = 2.5%,  $P = .07$ ; and pN1 = 1.0%,  $P = .27$ ), findings that were reinforced in multivariable analyses risk adjusted by clinicopathologic characteristics.

**CONCLUSION** Increased use of RS may help to better tailor treatment recommendations by stratifying patients with grade 3 disease into those who will and will not derive survival benefit and should be considered in all patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative T1c to T2, N0 to N1 disease.

JCO Precis Oncol. © 2019 by American Society of Clinical Oncology

## INTRODUCTION

The 21-gene Oncotype DX Breast Recurrence Score (RS; Genomic Health, Redwood City, CA) is a validated, predictive biomarker that helps to identify patients with breast cancer who benefit from the addition of adjuvant chemotherapy to endocrine therapy for estrogen receptor (ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative early-stage breast cancer.<sup>1–11</sup> The RS has been incorporated into clinical guidelines, including the National Comprehensive Cancer Network (version 1.2018; to be considered in patients with pN0 and pN1 status) and ASCO (to be considered in patients with pN0 status) guidelines.<sup>5,6</sup> The American Joint Committee on Cancer (AJCC) eighth edition cancer staging system also includes RS testing to downstage disease as part of the new pathologic prognostic staging system.<sup>7–9</sup> Specifically, patients with pT1 to 2 node-negative, ER-positive, HER2-negative breast cancer of any grade and a low RS (less than 11) are reduced to

prognostic stage group IA as a result of their favorable prognoses, which reflects the utility of a low RS to identify luminal A–type invasive breast cancers (ie, those with a low proliferation rate and high levels of ER and progesterone receptor [PR] expression) that do not benefit from chemotherapy.

The Trial Assigning Individualized Options for Treatment (TAILORx) (ClinicalTrials.gov identifier: [NCT00310180](https://clinicaltrials.gov/ct2/show/study/NCT00310180)) and Rx for Positive-Node, Endocrine-Responsive Breast Cancer (RxPONDER) (ClinicalTrials.gov identifier: [NCT01272037](https://clinicaltrials.gov/ct2/show/study/NCT01272037)) trials were designed to validate the RS prospectively and to determine the benefit of adjuvant chemotherapy for tumors with intermediate-range RS (ie, 11 to 25, not 18 to 30) in patients with pN0 and pN1 status, respectively.<sup>10,11</sup> TAILORx results have shown that the majority of tumors with low and intermediate RS do not benefit from chemotherapy,<sup>12</sup> and the results from RxPONDER are forthcoming.

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on July 18, 2019 and published at [ascopubs.org/journal/po](https://ascopubs.org/journal/po) on August 14, 2019; DOI <https://doi.org/10.1200/P0.19.00029>

## CONTEXT

### Key Objective

Although grade 3 is considered a poor prognostic factor in estrogen receptor–positive, human epidermal growth factor receptor 2–negative breast cancer, the predictive benefit of multigene recurrence score (RS) testing in this subgroup remains unclear.

### Knowledge Generated

Our analysis of the National Cancer Database that comprises more than 70% of all newly diagnosed cancers in the United States reveals that RS results in grade 3 T1c/T2 N0 and N1 breast cancer provide important discriminatory information with regard to chemotherapy benefit. In addition, our findings reveal significant variability in national patterns of RS testing and chemotherapy use for grade 3 tumors.

### Relevance

Expanding national clinical guidelines with regard to the value of RS testing and increasing use of RS testing in grade 3 tumors may facilitate de-escalation of therapy in those with a low RS.

Tumor grade is prognostic and independently associated with risk for recurrence; however, histopathologic high grade may not correlate well with the risk provided by the RS. In the PlanB trial (ClinicalTrials.gov identifier: [NCT01049425](https://clinicaltrials.gov/ct2/show/study/NCT01049425)), approximately 50% of grade 3 tumors had an RS less than 31.<sup>13</sup> The correlation of histologic grade with the predictive benefit of RS has not been assessed comprehensively. The proportion of grade 3 tumors in the TAILORx trial, although low, reflects the typical grade distribution, which accounts for 17.8% of all included tumors across scores, and it was 22% in the original cohort for the development of the RS.<sup>1</sup> As a result, the predictive benefit of RS and its potential for preventing overtreatment in grade 3 invasive breast carcinomas may be underappreciated. This study was undertaken to determine the national practices for ordering RS, treatment choices, and survival outcomes in patients with grade 3 breast cancer in a large, national data set.

## PATIENTS AND METHODS

### Data Source and Cohort Selection


The registry-derived, hospital-based National Cancer Database (NCDB) curated by the American College of Surgeons and American Cancer Society incorporates more than 70% of newly diagnosed cancers in the United States.<sup>14</sup> The NCDB routinely collects information on patient, tumor, demographic, and hospital characteristics in addition to information on any treatments administered within the first year of diagnosis. Patients newly diagnosed with invasive breast cancer (ie, third edition of the WHO International Classification of Diseases for Oncology morphologic codes 8500 and 8520 to 8524, with invasive behavior code 3, and breast topographic codes C50.0 to 50.9) from 2010 to 2015 were identified.<sup>15</sup> The NCDB began incorporating HER2 (using the 2007 ASCO/College of American Pathologists grading guidelines) and multigene prediction assay data as of 2010.<sup>16-18</sup> Women with

invasive ductal, lobular, or mixed carcinoma histologies; Nottingham grade data; and hormone receptor–positive, HER2-negative, pT1c to 2, and pN0 to 1 resected cancers without neoadjuvant systemic therapy, as determined from collaborative staging, breast cancer–specific site factors, were included (Fig 1).<sup>19</sup> Patients were excluded if they were younger than 20 years of age, had a prior diagnosis of cancer, were diagnosed at an index institution but treated entirely elsewhere, had evidence of distant metastasis, or did not receive surgery or hormonal therapy. Patients also were excluded if they lacked data about whether they received adjuvant chemotherapy or had RS testing. RS risk groups were categorized as low (less than 18), intermediate (18 to 30), and high (31 or higher) as originally defined by Paik et al.<sup>1</sup> Variables were coded according to the Facility Oncology Registry Data Standards Manual revised for 2013.<sup>20</sup>

### Variables of Interest

Our primary outcomes of interest were receipt of RS testing (yes/no; with no defined as multigene signature testing neither ordered nor performed) and overall survival (OS) using National Death Index data provided by the NCDB and defined as the time from date of diagnosis to death, with patients censored at the date of last follow-up available in the NCDB (December 31, 2015). Because of limited follow-up, the NCDB does not include survival information for patients diagnosed in the most recent year, which for this release was 2015. Our independent variables of interest for survival analyses were adjuvant chemotherapy receipt (yes/no) and RS score (low, intermediate, high). Adjuvant chemotherapy and radiotherapy receipt was defined as therapy documented postoperatively within 1 year of diagnosis. Control clinicopathologic variables were age, year of diagnosis, race/ethnicity, insurance status, Charlson-Deyo comorbidity index,<sup>21</sup> histology, AJCC pT classification, PR status, geographic location, Commission on Cancer–designated hospital type, and additional

**FIG 1.** Flow diagram of inclusion and exclusion criteria. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; RS, recurrence score.



treatments received beyond chemotherapy (ie, surgery type [breast conserving surgery/mastectomy], adjuvant radiotherapy [yes/no]).

**Statistical Analyses**

RS testing by clinicopathologic characteristics for all patients was compared using  $\chi^2$  tests and *t* tests, as appropriate. Multivariable logistic regression for receipt of RS testing was then performed, with stratification by pN status. To examine unadjusted differences in OS by chemotherapy receipt and RS, Kaplan-Meier method and log-rank test were used. The OS associated with adjuvant chemotherapy also was evaluated with multivariable Cox proportional hazards regression, after adjustment for all clinicopathologic variables of interest. Potential interaction effects of RS testing with adjuvant chemotherapy were explored using a previously described methodology.<sup>22</sup> To evaluate the accuracy of RS testing and Nottingham/Bloom-Richardson grade encoding, patients treated for breast cancer from 2010 to 2015 were queried from the cancer registry-submitted data from Brigham and Women’s Hospital and Dana-Farber Cancer Institute. The concordance between registry-submitted encoded data and the corresponding

Oncotype DX–reported RS and breast pathologist–assigned grade were evaluated for each patient. Statistical analyses were performed using Stata 14.2 software (StataCorp, College Station, TX), with a two-sided  $\alpha$ -level of 0.05 selected as significant. This study was approved by the Partners Healthcare institutional review board (2019P000950).

**RESULTS**

A total of 172,937 women with pT1c to 2 invasive breast carcinoma were included in our analysis. Of 126,827 patients with pN0 disease, 16.7% had grade 3 tumors (n = 21,144), and of the 46,110 patients with pN1 disease, 21.1% had grade 3 tumors (n = 9,720). Clinicopathologic characteristics are listed in Table 1.

**Characteristics Associated With RS Testing for pN0 Disease**

In patients with pN0 grade 3 tumors, 64.1% (n = 13,558) had RS testing compared with 59.2% (n = 22,267) and 65.7% (n = 44,708) with grade 1 and 2 tumors, respectively (P < .001). There was increasing use of RS testing between 2010 to 2015 in grade 3 disease (from

**TABLE 1.** Characteristics Associated With RS Testing for Grade 3 Disease, Stratified by pN Status

Characteristic	pN0				pN1					
	Total (No.)	Had RS Testing (%)	OR	Multivariable Logistic Regression 95% CI	P	Total (No.)	Had RS Testing (%)	OR	Multivariable Logistic Regression 95% CI	P
No. of patients	21,144	64.1	NA	NA		9,720	29.2	NA	NA	
Age, years										
< 50	4,940	63.6	0.81	0.74 to 0.89	< .001	2,865	22.8	0.80	0.70 to 0.92	.002
50-59	5,552	70.6	Ref			2,699	29.4	Ref		
60-69	6,201	71.2	1.06	0.97 to 1.16	.21	2,340	36.5	1.46	1.28 to 1.67	< .001
≥ 70	4,451	46.7	0.41	0.37 to 0.46	< .001	1,816	29.6	1.14	0.96 to 1.36	.15
Year of diagnosis										
2010	2,671	53.2	Ref			1,339	16.9	Ref		
2011	3,207	58.8	1.28	1.14 to 1.44	< .001	1,495	24.5	1.65	1.35 to 2.00	< .001
2012	3,567	63.1	1.54	1.38 to 1.73	< .001	1,670	28.9	1.99	1.64 to 2.40	< .001
2013	3,937	64.7	1.65	1.48 to 1.85	< .001	1,835	31.5	2.33	1.93 to 2.80	< .001
2014	3,858	68.3	1.94	1.73 to 2.17	< .001	1,706	34.2	2.67	2.22 to 3.21	< .001
2015	3,904	72.3	2.46	2.19 to 2.75	< .001	1,675	36.0	2.90	2.41 to 3.49	< .001
Comorbidity index										
0	17,494	65.2	Ref			8,115	29.3	Ref		
1	3,021	60.1	0.90	0.83 to 0.99	.03	1,280	29.1	0.95	0.83 to 1.09	.48
2	478	55.0	0.75	0.61 to 0.91	.004	249	28.9	0.88	0.66 to 1.18	.40
3	151	55.6	0.87	0.61 to 1.24	.44	76	25.0	0.71	0.41 to 1.22	.22
Race/ethnicity										
White	16,551	65.1	Ref			7,380	30.2	Ref		
Black	2,377	60.3	0.80	0.72 to 0.89	< .001	1,198	26.4	0.87	0.75 to 1.02	.08
Asian/Pacific Islander	873	65.2	0.95	0.80 to 1.11	.50	412	27.7	0.99	0.77 to 1.26	.93
Hispanic	1,046	58.0	0.76	0.66 to 0.88	< .001	572	23.1	0.75	0.60 to 0.95	.02
Other/unknown	297	61.3	0.76	0.59 to 0.99	.04	158	32.9	1.14	0.79 to 1.66	.48
Primary payer										
Not insured	335	56.1	Ref			224	22.8	Ref		
Private insurance	12,072	68.9	1.50	1.17 to 1.90	.001	5,729	29.0	1.25	0.88 to 1.79	.21
Medicaid	1,392	60.2	1.27	0.97 to 1.65	.08	789	24.0	1.02	0.69 to 1.51	.91
Medicare	6,948	56.9	1.35	1.05 to 1.74	.02	2,784	31.4	1.14	0.79 to 1.66	.48
Other government	185	62.2	1.30	0.86 to 1.97	.22	112	35.7	1.70	0.98 to 2.96	.06
Unknown	212	66.0	1.51	1.02 to 2.23	.04	82	28.1	1.03	0.55 to 1.91	.93

(Continued on following page)

**TABLE 1.** Characteristics Associated With RS Testing for Grade 3 Disease, Stratified by pN Status (Continued)

Characteristic	pN0				pN1					
	Multivariable Logistic Regression				Multivariable Logistic Regression					
	Total (No.)	Had RS Testing (%)	OR	95% CI	P	Total (No.)	Had RS Testing (%)	OR	95% CI	P
Hospital type										
Community cancer program	1,923	57.9	Ref			869	27.9	Ref		
Comprehensive cancer center	9,565	63.3	1.22	1.09 to 1.35	< .001	4,282	28.8	1.03	0.87 to 1.22	.72
Academic/research	6,264	69.0	1.42	1.27 to 1.60	< .001	2,875	32.9	1.27	1.07 to 1.52	.01
Integrated cancer network program	2,180	64.7	1.24	1.08 to 1.42	.003	923	29.9	1.09	0.88 to 1.35	.43
Hospital location										
New England	1,266	66.8	Ref			540	27.0	Ref		
Middle Atlantic	3,107	70.7	1.31	1.13 to 1.52	< .001	1,556	33.2	1.33	1.06 to 1.66	.01
South Atlantic	4,247	65.8	1.12	0.97 to 1.29	.14	1,846	30.1	1.25	0.99 to 1.56	.06
East North Central	3,736	66.3	1.08	0.94 to 1.25	.29	1,634	32.1	1.31	1.04 to 1.64	.02
East South Central	1,127	64.2	0.96	0.80 to 1.15	.67	438	32.0	1.32	0.99 to 1.77	.06
West North Central	1,796	64.3	0.97	0.82 to 1.14	.70	833	29.5	1.13	0.88 to 1.45	.35
West South Central	1,232	56.0	0.73	0.61 to 0.87	< .001	535	23.6	0.90	0.67 to 1.20	.46
Mountain	932	64.8	1.07	0.88 to 1.30	.48	435	32.6	1.45	1.08 to 1.94	.01
Pacific	2,489	56.9	0.74	0.64 to 0.87	< .001	1,132	26.5	1.08	0.85 to 1.38	.53
AJCC pT										
1c	11,687	69.0	Ref			3,507	36.1	Ref		
2	9,457	58.1	0.66	0.62 to 0.70	< .001	6,213	25.3	0.65	0.59 to 0.72	< .001
Histology										
IDC	18,854	64.2	Ref			8,625	29.1	Ref		
ILC	826	61.6	0.99	0.85 to 1.16	.89	328	33.5	1.26	0.98 to 1.61	.07
IMC	1,464	64.8	1.01	0.90 to 1.15	.82	767	29.2	0.97	0.82 to 1.15	.74
PR status										
Negative	3,941	55.4	Ref			1,439	22.1	Ref		
Positive	17,182	66.1	1.51	1.39 to 1.63	< .001	8,265	30.5	1.47	1.28 to 1.69	< .001
Standard surgery/RT										
Yes (lumpectomy with RT or mastectomy only)	18,898	65.5	Ref			7,085	32.6	Ref		
No (lumpectomy only)	832	38.2	0.44	0.38 to 0.51	< .001	238	21.9	0.53	0.38 to 0.75	< .001
No (mastectomy with RT)	515	52.8	0.69	0.57 to 0.84	< .001	2,317	19.3	0.55	0.48 to 0.62	< .001

NOTE: Boldface indicates significance at  $P < .05$ .  
 Abbreviations: AJCC, American Joint Committee on Cancer; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; IMC, invasive mixed carcinoma; NA, not applicable; OR, odds ratio; PR, progesterone receptor; Ref, reference; RS, recurrence score; RT, radiotherapy.

53.2% to 72.3%;  $P < .001$ ). In multivariable logistic analyses, receipt of RS testing for grade 3 disease was significantly associated with ages 50 to 59 years; a more recent (*v* earlier) diagnosis; lower comorbidity score; white race; private or Medicare insurance (*v* uninsured); and tumors that were pT1c, PR positive, or treated with standard local therapy (*v* nonstandard; [Table 1](#)).

### Characteristics Associated With RS Testing for pN1 Disease

In patients with pN1 grade 3 tumors, 29.2% ( $n = 2,840$ ) had RS testing compared with 47.4% ( $n = 4,937$ ) and 42.7% ( $n = 11,083$ ) with grade 1 and 2 tumors, respectively ( $P < .001$ ). We observed an increasing use of RS testing between 2010 and 2015 in pN1 grade 3 disease (from 16.9% to 36.0%;  $P < .001$ ). In multivariable logistic analyses, receipt of RS testing was significantly associated with ages 50 to 69 years; a more recent diagnosis; lower comorbidity score; non-Hispanic race/ethnicity; and tumors that were pT1c, PR positive, or treated with standard local therapy ([Table 1](#)).

### Associations of Chemotherapy and OS for pN0 Grade 3 Disease by RS

In multivariable logistic regression analyses, intermediate RS (odds ratio [OR], 15.23; 95% CI, 13.20 to 17.58;  $P < .001$ ) and high RS (OR, 141.55; 95% CI, 118.58 to 168.97;  $P < .001$ ) were associated with receipt of adjuvant chemotherapy compared with low RS ([Table 2](#)). Adjuvant chemotherapy receipt also was associated with younger patients; patients who were diagnosed earlier in the study period (*v* more recently); patients without comorbidity, pT2 tumors, invasive ductal carcinoma, and PR-negative status; and patients who received standard local therapy (*v* nonstandard; [Table 2](#)).

The median follow-up for patients with pN0 grade 3 disease was 41.1 months (interquartile range, 28.8-56.3 months), and 5.3% of patients died during the study period. In the group of patients without RS testing, 52.2% received chemotherapy in addition to endocrine therapy, which demonstrated an unadjusted absolute improvement in 5-year OS rate of 10.3% ( $P < .001$ ; [Table 3](#); [Fig 2A](#)). For patients with low RS, 9.1% received chemotherapy, which was not associated with a significantly increased 5-year unadjusted OS rate ( $P = .07$ ; [Table 3](#); [Fig 2A](#)). In contrast, 54.9% of patients with intermediate RS and 89.4% of patients with high RS received chemotherapy, with both groups demonstrating associations with an improved unadjusted 5-year OS rate of 2.5% ( $P = .002$ ) and 12.2% ( $P < .001$ ), respectively ([Table 3](#); [Fig 2A](#)).

The OS improvements associated with adjuvant chemotherapy in patients with pN0 grade 3 disease also were assessed in multivariable Cox proportional hazards regression analyses ([Table 4](#)). In patients with grade 3 disease with high RS or who had no RS testing, adjuvant chemotherapy demonstrated significantly improved OS in

multivariable analyses compared with those who did not receive chemotherapy (hazard ratio [HR], 0.63 [95% CI, 0.43 to 0.90;  $P = .01$ ] and 0.51 [95% CI, 0.40 to 0.64;  $P < .001$ ], respectively), whereas low and intermediate RS were not associated with an OS benefit from adjuvant chemotherapy (reference no chemotherapy; HR, 0.50 [95% CI, 0.16 to 1.61;  $P = .25$ ] and 0.71 [95% CI, 0.49 to 0.90;  $P = .07$ ], respectively). Increasing age at diagnosis, comorbidity index, pT classification, and nonstandard lumpectomy-only management all demonstrated worse OS, whereas Asian/Pacific Islander and Hispanic race (reference white), management at an academic/research institution (reference community cancer program), invasive lobular carcinoma histology, and PR-positive status were associated with improved OS ([Table 4](#)).

### Associations of Chemotherapy and OS for pN1 Grade 3 Disease by RS Testing

In multivariable logistic analyses, intermediate (OR, 6.62; 95% CI, 5.28 to 8.30;  $P < .001$ ) and high (OR, 36.92; 95% CI, 26.73 to 50.99;  $P < .001$ ) RS were associated with receiving adjuvant chemotherapy compared with low RS ([Table 2](#)). Treatment with adjuvant chemotherapy also was associated with patients who were younger, privately insured, without comorbidity, and PR negative and who had received standard local therapy ([Table 2](#)).

The median follow-up of patients with pN1 grade 3 disease was 41.9 months (interquartile range, 29.0-56.7 months), and 8.0% of patients died during the study period. In the group of patients without RS testing, 82.8% received chemotherapy in addition to endocrine therapy, which was associated with an absolute improvement in 5-year OS rate of 20.1% ( $P < .001$ ; [Table 3](#); [Fig 2B](#)). For patients with low RS, 25.9% received chemotherapy, and this was not associated with a significantly increased unadjusted 5-year OS ( $P = .27$ ; [Table 3](#); [Fig 2B](#)). In contrast, 64.4% of patients with intermediate RS and 88.3% with high RS received chemotherapy, with both groups demonstrating absolute improvements in 5-year OS rate of 7.5% ( $P = .02$ ) and 25.5% ( $P < 0.001$ ), respectively ([Table 3](#); [Fig 2B](#)).

The OS benefits of adjuvant chemotherapy in patients with pN1 grade 3 disease also were assessed in multivariable Cox proportional hazards regression analyses ([Table 4](#)). As in pN0 disease, patients with pN1 grade 3 disease with high RS and no RS testing showed significantly improved OS with adjuvant chemotherapy (HR, 0.24 [95% CI, 0.13 to 0.47;  $P < .001$ ] and 0.42 [95% CI, 0.33 to 0.53;  $P < .001$ ], respectively), whereas low and intermediate RS did not (HR, 0.81 [95% CI, 0.33 to 1.98;  $P = .64$ ] and 0.67 [95% CI, 0.35 to 1.27;  $P = 0.22$ ], respectively). In addition to increasing age at diagnosis, comorbidity index, AJCC pT classification, PR-negative status, and nonstandard lumpectomy-only management all demonstrated worse OS. OS also significantly varied by geographical location ([Table 4](#)).

**TABLE 2.** Characteristics Associated With Adjuvant Chemotherapy for Grade 3 Disease, Stratified by pN Status

Characteristic	pN0					pN1				
	Total (No.)	Had CT (%)	OR	95% CI	P	Total (No.)	Had CT (%)	OR	95% CI	P
No. of patients	21,144	53.1	NA			9,720	76.0	NA		
RS										
No RS	7,586	52.2	16.66	14.42 to 19.25	< .001	6,880	82.8	21.87	17.87 to 26.77	< .001
Low	3,591	9.1	Ref			821	25.9	Ref		
Intermediate	5,304	54.9	15.23	13.20 to 17.58	< .001	1,188	64.4	6.62	5.28 to 8.30	< .001
High	4,332	89.4	141.55	118.58 to 168.97	< .001	726	88.3	36.92	26.73 to 50.99	< .001
Age, years										
< 50	4,940	74.8	1.83	1.63 to 2.05	< .001	2,865	91.8	1.39	1.13 to 1.71	.002
50-59	5,552	63.1	Ref			2,699	85.7	Ref		
60-69	6,201	49.9	0.57	0.51 to 0.63	< .001	2,340	75.9	0.63	0.53 to 0.76	< .001
≥ 70	4,451	21.1	0.12	0.11 to 0.14	< .001	1,816	37.0	0.09	0.08 to 0.12	< .001
Year of diagnosis										
2010	2,671	56.8	Ref			1,339	78.4	Ref		
2011	3,207	55.0	0.95	0.83 to 1.10	.53	1,495	77.1	1.11	0.88 to 1.40	.37
2012	3,567	52.3	0.93	0.81 to 1.07	.33	1,670	76.9	1.12	0.89 to 1.39	.34
2013	3,937	53.1	0.93	0.81 to 1.07	.33	1,835	76.6	1.12	0.90 to 1.40	.30
2014	3,858	53.1	0.85	0.74 to 0.98	.02	1,706	73.3	0.84	0.67 to 1.05	.12
2015	3,904	49.9	0.74	0.64 to 0.85	< .001	1,675	74.5	1.09	0.87 to 1.36	.45
Comorbidity index										
0	17,494	54.8	Ref			8,115	78.3	Ref		
1	3,021	46.4	0.89	0.80 to 1.00	.04	1,280	67.9	0.83	0.70 to 0.99	.03
2	478	38.9	0.79	0.62 to 1.01	.06	249	57.0	0.57	0.41 to 0.79	.001
3	151	34.4	0.65	0.42 to 1.02	.06	76	36.8	0.31	0.18 to 0.55	< .001
Race/ethnicity										
White	16,551	51.5	Ref			7,380	74.9	Ref		
Black	2,377	58.4	0.99	0.87 to 1.12	.82	1,198	78.6	0.89	0.73 to 1.07	.22
Asian/Pacific Islander	873	61.5	1.17	0.97 to 1.42	.11	412	80.3	1.04	0.75 to 1.45	.81
Hispanic	1,046	58.4	1.08	0.90 to 1.29	.42	572	82.5	1.27	0.95 to 1.71	.11
Other/unknown	297	57.9	1.04	0.76 to 1.43	.81	158	76.0	1.29	0.78 to 2.14	.32

(Continued on following page)

**TABLE 2.** Characteristics Associated With Adjuvant Chemotherapy for Grade 3 Disease, Stratified by pN Status (Continued)

pN0 pN1

Characteristic	Multivariable Logistic Regression				Multivariable Logistic Regression					
	Total (No.)	Had CT (%)	OR	95% CI	P	Total (No.)	Had CT (%)	OR	95% CI	P
Primary payer										
Not insured	335	61.2	Ref			224	84.8	Ref		
Private insurance	12,072	63.2	1.20	0.89 to 1.62	.23	5,729	85.8	1.70	1.10 to 2.61	<b>.02</b>
Medicaid	1,392	63.2	0.94	0.68 to 1.31	.73	789	84.9	1.31	0.81 to 2.14	.27
Medicare	6,948	33.0	0.80	0.59 to 1.09	.16	2,784	52.5	1.04	0.66 to 1.62	.87
Other government	185	61.6	1.41	0.85 to 2.32	.18	112	82.1	1.38	0.66 to 2.88	.39
Unknown	212	50.9	0.78	0.49 to 1.26	.32	82	76.8	1.52	0.72 to 3.21	.27
Hospital type										
Community cancer program	1,923	48.5	Ref			869	73.5	Ref		
Comprehensive cancer center	9,565	50.2	1.09	0.96 to 1.25	.20	4,282	73.4	0.91	0.73 to 1.13	.39
Academic/research	6,264	53.2	1.08	0.94 to 1.24	.26	2,875	75.3	0.88	0.70 to 1.10	.27
Integrated cancer network program	2,180	52.3	1.13	0.95 to 1.34	.16	923	76.6	1.02	0.77 to 1.34	.90
Hospital location										
New England	1,266	51.1	Ref			540	79.1	Ref		
Middle Atlantic	3,107	49.6	1.03	0.86 to 1.24	.72	1,556	72.6	0.85	0.63 to 1.14	.28
South Atlantic	4,247	51.1	0.92	0.77 to 1.10	.35	1,846	74.2	0.83	0.62 to 1.11	.21
East North Central	3,736	52.9	1.10	0.92 to 1.31	.30	1,634	74.9	0.94	0.69 to 1.26	.66
East South Central	1,127	53.1	1.12	0.90 to 1.40	.30	438	75.3	0.92	0.63 to 1.35	.67
West North Central	1,796	52.2	1.08	0.89 to 1.32	.42	833	76.1	1.05	0.75 to 1.46	.79
West South Central	1,232	50.7	0.92	0.74 to 1.14	.44	535	74.8	0.88	0.61 to 1.26	.48
Mountain	932	49.1	0.88	0.70 to 1.12	.30	435	70.3	0.68	0.46 to 0.99	<b>.04</b>
Pacific	2,489	50.1	0.86	0.72 to 1.04	.12	1,132	73.6	0.74	0.54 to 1.02	.07
AJCC pT										
1c	11,687	48.3	Ref			3,507	74.1	Ref		
2	9,457	59.1	1.66	1.54 to 1.80	<b>&lt; .001</b>	6,213	77.1	1.08	0.95 to 1.22	.27
Histology										
IDC	18,854	54.8	Ref			8,625	76.5	Ref		
ILC	826	30.8	0.61	0.50 to 0.74	<b>&lt; .001</b>	328	66.8	0.93	0.69 to 1.26	.64
IMC	1,464	44.4	0.84	0.72 to 0.97	<b>.02</b>	767	74.8	0.93	0.74 to 1.16	.53

(Continued on following page)



**TABLE 2.** Characteristics Associated With Adjuvant Chemotherapy for Grade 3 Disease, Stratified by pN Status (Continued)

Characteristic	pN0					pN1					
	Total (No.)	Had CT (%)	Multivariable Logistic Regression			Total (No.)	Had CT (%)	Multivariable Logistic Regression			
			OR	95% CI	P			OR	95% CI	P	
PR status											
Negative	3,941	75.0	Ref		1,439	83.7	Ref				
Positive	17,182	48.1	0.44	0.40 to 0.49	8,265	74.7	0.62	0.51 to 0.75			< .001
Standard surgery/RT											
Yes (lumpectomy with RT or mastectomy only)	18,898	54.5	Ref		7,085	73.1	Ref				
No (lumpectomy only)	832	21.9	0.36	0.28 to 0.44	238	47.1	0.51	0.37 to 0.71			< .001
No (mastectomy with RT)	515	71.7	2.06	1.60 to 2.66	2,317	88.2	2.30	1.94 to 2.74			< .001

NOTE. Boldface indicates significance at  $P < .05$ .

Abbreviations: AJCC, American Joint Committee on Cancer; CT, chemotherapy; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; IMC, invasive mixed carcinoma; NA, not applicable; OR, odds ratio; PR, progesterone receptor; Ref, reference; RS, recurrence score; RT, radiotherapy.

**TABLE 3.** Kaplan-Meier Estimates of Overall Survival Associated With Adjuvant Chemotherapy in Patients With Grade 3 Invasive Breast Cancer, Stratified by pN Status and RS

RS*	Total (No.)	Had Chemotherapy (%)	5-Year Overall Survival Rate, % (95% CI)		P
			No Chemotherapy	Chemotherapy	
pN0					
Low	3,591	9.1	96.3 (95.0 to 97.2)	98.8 (94.9 to 99.7)	.07
Intermediate	5,304	54.9	93.0 (90.8 to 94.7)	95.5 (94.0 to 96.6)	<b>.002</b>
High	4,332	89.4	79.6 (72.4 to 85.1)	91.8 (90.2 to 93.1)	<b>&lt; .001</b>
No RS	7,586	52.2	83.3 (81.3 to 85.0)	93.6 (92.4 to 94.7)	<b>&lt; .001</b>
pN1					
Low	821	25.9	92.0 (86.9 to 95.2)	93.0 (80.7 to 97.6)	.27
Intermediate	1,188	64.4	85.7 (77.5 to 91.1)	93.2 (88.4 to 96.1)	<b>.02</b>
High	726	88.3	66.9 (48.6 to 79.9)	92.4 (88.1 to 95.2)	<b>&lt; .001</b>
No RS	6,880	82.8	70.6 (66.5 to 74.3)	90.7 (89.5 to 91.8)	<b>&lt; .001</b>

NOTE. Boldface indicates significance at  $P < .05$ .

Abbreviation: RS, recurrence score.

\*In 2.4% of patients ( $n = 331$ ) with pN0 and 3.7% ( $n = 105$ ) with pN1 grade 3 tumors who underwent RS testing, the RS score was not available.

### Evaluation of Grade 3 and RS Coding Accuracy

We also examined our multi-institutional cohort to validate registry-submitted grade and RS encoding. Of 351 adults with invasive breast carcinoma who had RS testing between 2010 and 2015, 74.7% ( $n = 259$ ) were encoded and submitted for inclusion into cancer registries. Nottingham/Bloom-Richardson grade was missing or incorrectly encoded in 6.6% of patients ( $n = 17$ ), including 8.1% ( $n = 3$ ) with grade 3 disease. The numerical RS was missing in 15.4% of registry-submitted patients ( $n = 40$ ) and incorrectly encoded in 3.9% ( $n = 10$ ). In particular, of the 37 grade 3 registry-submitted institutional patients with RS testing, 16.2% ( $n = 6$ ) had missing scores in registry data, and only 3.2% ( $n = 1$ ) were incorrectly encoded (as no RS instead of an actual RS of 22).

### DISCUSSION


In this large national cohort, we evaluated the use of RS, use of adjuvant chemotherapy, and OS for women with breast cancer, with a focus on high tumor grade. We found that 30.0% of pN0 and 27.1% of pN1 grade 3 invasive breast cancers had a low RS, which was not associated with an OS benefit from chemotherapy. Of note, chemotherapy was associated with significant OS improvements in grade 3 invasive breast cancers with high RS, and although associated with improved OS in univariable analyses, intermediate RS was not predictive of significant chemotherapy OS benefit when risk adjusted for clinicopathologic characteristics. The incorporation of RS testing into the clinical decision making for grade 3 invasive breast cancers may help to tailor treatment recommendations for these patients. To our knowledge, these findings represent the largest analysis to date of the potential impact of RS on the outcomes and management of grade 3 tumors and

suggest that the assumption that all pT1c/2 pN0/1, ER-positive histopathologic grade 3 tumors are high risk and will consequently benefit from adjuvant chemotherapy may be unmerited.

Although we await the RxPONDER trial final results, the data presented here suggest that patients with a pT1c/2 NO/1 grade 3 tumor with high RS derive benefit from chemotherapy (92% 5-year OS with chemotherapy v 67% to 79% without), whereas grade 3 tumors with low and intermediate RS do not. Our results further reinforce the utility of broad RS testing in grade 3 tumors and suggest that RS can help to distinguish the anticipated chemotherapy benefit among this heterogeneous group of tumors.

The rate of RS testing is less in pN1 disease than in pN0 disease (36% in 2015 v 72% in pN0) but is expanding in both groups because the importance of tumor biology is increasingly recognized. In our study, the increased use of RS testing in pN0 grade 3 disease (64.1%) and lower rate of chemotherapy (9.1%) in patients with low RS suggest that clinical practice is increasingly incorporating RS results into decision trees for pN0 grade 3 disease. However, our findings also suggest that a significant proportion of patients with pN1 grade 3 disease who do not undergo RS testing may be overtreated and receive chemotherapy with no added OS benefit. We also find that nationally, significant variability exists in grade 3 RS testing patterns by hospital type and geographic location and even in patient insurance status and race/ethnicity, which suggests opportunities for more-detailed guidance from national guidelines for RS testing, particularly for grade 3 tumors.

We found that a high proportion of patients designated as having a high histologic grade had a low RS (less 18)—27.1% with pN0 and 30.0% with pN1 disease—results that



**FIG 2.** Overall survival (OS) in patients with grade 3 invasive breast cancer, stratified by recurrence score (RS). Adjuvant chemotherapy OS estimated by Kaplan-Meier method for patients with (A) pN0 and (B) pN1 grade 3 invasive breast cancer, stratified by RS and adjuvant chemotherapy, with an underlying number at risk table. Adjuvant chemotherapy (solid lines) was associated with significantly better median OS than no adjuvant chemotherapy (dashed lines) for intermediate, high, and no RS.

are notably higher than those reported in the PlanB trial (18% of grade 3 tumors).<sup>13</sup> However, our findings are in keeping with those reported in the Microarray in Node-Negative (or 1-3 Positive Lymph Node) Disease May Avoid Chemotherapy (MINDACT) trial, where patients were stratified by both anatomic and genomic risk using a 70-gene signature. In MINDACT, 28.6% of tumors deemed to be of high clinical risk had low genomic risk and were unlikely to benefit from chemotherapy.<sup>23</sup> In the published TAILORx trial data, intermediate RS (11 to 25) tumors in postmenopausal women did not demonstrate clear benefit

from chemotherapy; however, this trial was in patients with NO disease with mostly small tumors, excluded those with an intermediate RS of 26 to 30, and only included a small proportion (17.8%) of patients with grade 3 disease, all of which are limiting comparisons within our study that included a substantial number of T2 tumors in NO disease.<sup>12</sup> Our analyses are constrained by several limitations of the NCDB. Of note, despite representing a majority of patients with cancer in the United States and forming the basis of AJCC staging guidelines, the lack of centralized clinical or pathologic review may limit the accuracy of encoded data.

**TABLE 4.** Multivariable Cox Proportional Hazards Regression for the Overall Survival Associated With Adjuvant Chemotherapy in Patients With Grade 3 Invasive Breast Cancer, Stratified by pN Status

Variable	pN0			pN1		
	HR	95% CI	P	HR	95% CI	P
RS by chemotherapy						
No RS						
Chemotherapy (Ref no chemotherapy)	0.51	0.40 to 0.64	< .001	0.42	0.33 to 0.53	< .001
Low						
Chemotherapy (Ref no chemotherapy)	0.50	0.16 to 1.61	.25	0.81	0.33 to 1.98	.64
Intermediate						
Chemotherapy (Ref no chemotherapy)	0.71	0.49 to 1.03	.07	0.67	0.35 to 1.27	.22
High						
Chemotherapy (Ref no chemotherapy)	0.63	0.43 to 0.90	.01	0.24	0.13 to 0.47	< .001
Age, years						
< 50	0.90	0.67 to 1.20	.46	0.71	0.53 to 0.96	.03
50-59	Ref			Ref		
60-69	1.29	1.02 to 1.62	.03	1.00	0.77 to 1.30	1.00
≥ 70	2.07	1.59 to 2.70	< .001	1.64	1.20 to 2.23	.002
Year of diagnosis						
2010	Ref			Ref		
2011	1.06	0.88 to 1.28	.55	1.37	1.08 to 1.72	.008
2012	0.96	0.77 to 1.19	.70	1.28	0.99 to 1.66	.06
2013	1.05	0.82 to 1.34	.69	1.33	0.99 to 1.79	.06
2014	1.29	0.95 to 1.75	.11	1.79	1.25 to 2.58	.002
Comorbidity index						
0	Ref			Ref		
1	1.43	1.20 to 1.69	< .001	1.35	1.10 to 1.67	.004
2	2.83	2.15 to 3.73	< .001	1.76	1.20 to 2.58	.004
3	2.95	1.89 to 4.60	< .001	3.68	2.26 to 6.01	< .001
Race/ethnicity						
White	Ref			Ref		
Black	1.02	0.82 to 1.26	.88	1.06	0.83 to 1.35	.65
Asian/Pacific Islander	0.50	0.29 to 0.87	.02	0.66	0.38 to 1.17	.15
Hispanic	0.63	0.40 to 0.99	.045	0.67	0.43 to 1.04	.08
Other/unknown	0.63	0.28 to 1.42	.26	0.59	0.24 to 1.43	.24
Primary payer						
Not insured	Ref			Ref		
Private insurance	0.74	0.40 to 1.36	.34	0.74	0.43 to 1.26	.27
Medicaid	0.92	0.47 to 1.80	.81	0.85	0.47 to 1.57	.61
Medicare	0.99	0.53 to 1.83	.97	0.91	0.52 to 1.57	.72
Other government	1.64	0.69 to 3.88	.26	0.91	0.33 to 2.53	.86
Unknown	0.77	0.29 to 1.99	.58	1.29	0.49 to 3.34	.61
Hospital type						
Community cancer program	Ref			Ref		
Comprehensive cancer center	0.86	0.69 to 1.07	.17	0.74	0.57 to 0.97	.03
Academic/research	0.74	0.59 to 0.94	.01	0.84	0.63 to 1.11	.21
Integrated cancer network program	0.83	0.62 to 1.11	.21	0.92	0.66 to 1.30	.65

(Continued on following page)

**TABLE 4.** Multivariable Cox Proportional Hazards Regression for the Overall Survival Associated With Adjuvant Chemotherapy in Patients With Grade 3 Invasive Breast Cancer, Stratified by pN Status (Continued)

Variable	pN0			pN1		
	HR	95% CI	P	HR	95% CI	P
Hospital location						
New England	Ref			Ref		
Middle Atlantic	1.08	0.78 to 1.51	.64	1.82	1.14 to 2.92	<b>.01</b>
South Atlantic	0.92	0.66 to 1.27	.61	1.84	1.15 to 2.94	<b>.01</b>
East North Central	1.07	0.78 to 1.48	.66	1.57	0.98 to 2.52	.06
East South Central	1.06	0.72 to 1.57	.75	1.95	1.10 to 3.44	<b>.02</b>
West North Central	0.93	0.65 to 1.34	.71	1.79	1.08 to 2.96	<b>.02</b>
West South Central	0.75	0.49 to 1.14	.18	1.94	1.14 to 3.31	<b>.02</b>
Mountain	0.97	0.64 to 1.48	.90	1.55	0.86 to 2.79	.14
Pacific	0.82	0.57 to 1.16	.26	1.70	1.03 to 2.79	<b>.04</b>
AJCC pT						
2 (Ref 1c)	1.99	1.73 to 2.30	<b>&lt; .001</b>	1.45	1.20 to 1.75	<b>&lt; .001</b>
Histology						
IDC	Ref			Ref		
ILC	0.60	0.41 to 0.88	<b>.01</b>	1.26	0.86 to 1.86	.23
IMC	0.81	0.61 to 1.09	.17	0.94	0.69 to 1.29	.71
PR status						
Positive (Ref negative)	0.70	0.59 to 0.82	<b>&lt; .001</b>	0.54	0.45 to 0.66	<b>&lt; .001</b>
Standard surgery/RT						
Yes (lumpectomy with RT or mastectomy only)	Ref			Ref		
No (lumpectomy only)	1.94	1.55 to 2.44	<b>&lt; .001</b>	1.99	1.46 to 2.72	<b>&lt; .001</b>
No (mastectomy with RT)	1.03	0.66 to 1.59	.91	0.97	0.78 to 1.21	.80

NOTE. Boldface indicates significance at  $P < .05$ .

Abbreviations: AJCC, American Joint Committee on Cancer; HR, hazard ratio; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; IMC, invasive mixed carcinoma; PR, progesterone receptor; Ref, reference; RS, recurrence score; RT, radiotherapy.

However, in our multi-institutional cohort of registry-submitted patients, 92% with grade 3 disease demonstrated accurate grade coding of whom only 3% had an incorrectly encoded RS, which suggests that key breast cancer-specific factors are encoded into national registries with encouraging accuracy. In addition, the NCDB only includes OS data, which precludes assessment of breast cancer-specific, progression-free, or recurrence-free survival, end points that may be of greater relevance in the clinical setting. Because of limited follow-up, the NCDB does not incorporate survival data for patients diagnosed in the most recent year. As such, our median follow-up is only 41.3 months and the event rate only 6.2%; nevertheless, we incorporated a large sample size that powered the detection of clinically relevant differences in RS predictive value. Finally, the NCDB lacks detailed information about type, dose, and duration of chemotherapeutic and hormonal treatments and, in particular, has limited granular data about the factors that influence clinical decision making about when to administer adjuvant chemotherapy.

For example, across all patients with grade 3 disease who were not administered chemotherapy, the NCDB only encoded a reason in 27% (21% because chemotherapy was contraindicated and 7% because chemotherapy was recommended but refused by the patient). To help to address the lack of data about patient contraindications, we included Charlson-Deyo comorbidity index data in our risk-adjusted analyses, and higher indices were associated with reduced chemotherapy use. The NCDB also lacks patient menopausal status and only began encoding HER2 status as of 2010. Furthermore, the NCDB does not have information on why RS was or was not sent, which introduces the potential for bias in whom is anticipated to benefit or not benefit from chemotherapy on the basis of additional patient and physician factors that were not captured in our data set.

In conclusion, our data show significant clinical value for RS testing in patients with grade 3 breast cancer to predict which patients are likely to show early benefit or not from

the addition of chemotherapy. Furthermore, our findings show significant variability in national patterns of RS testing and chemotherapy use for grade 3 disease, which suggests opportunities for more comprehensive national guidelines for RS testing in high-grade tumors. These results fill a gap

as we await the final RxPONDER trial results and provide additional data to the reported results of the TAILORx trial to help clinicians to identify patients who may safely omit chemotherapy without compromising their outcomes.

## AFFILIATIONS

<sup>1</sup>Brigham and Women's Hospital, Boston, MA

<sup>2</sup>Harvard Medical School, Boston, MA

<sup>3</sup>Dana-Farber Cancer Institute, Boston, MA

## CORRESPONDING AUTHOR

Jane E. Brock, MBBS, PhD, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115; Twitter: @BrighamWomens, @DanaFarber; e-mail: jebrook@bwh.harvard.edu.

## EQUAL CONTRIBUTION

E.A.M. and J.E.B. contributed equally and should be considered co-senior authors.

## PRIOR PRESENTATION

Presented at the USCAP 2018 Annual Meeting, Vancouver, British Columbia, Canada, March 17-23, 2018.

## SUPPORT

Supported by the National Institutes of Health (5T32-HL007627; J.B.I.), the American Cancer Society (125912-MRSG-14-240-01-CPBP; R.A.F.), and Susan G. Komen (CCRRCR18552788; R.A.F.).

## AUTHOR CONTRIBUTIONS

**Conception and design:** J. Bryan Iorgulescu, Rachel A. Freedman, Jane E. Brock

**Administrative support:** J. Bryan Iorgulescu, Susan C. Lester, Jane E. Brock

**Provision of study material or patients:** Susan C. Lester

**Collection and assembly of data:** J. Bryan Iorgulescu, Susan C. Lester

**Data analysis and interpretation:** J. Bryan Iorgulescu, Rachel A. Freedman, Susan C. Lester, Elizabeth A. Mittendorf

**Manuscript writing:** All authors

**Final approval of manuscript:** All authors

**Accountable for all aspects of the work:** All authors

## AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [ascopubs.org/po/author-center](http://ascopubs.org/po/author-center).

**Rachel A. Freedman**

**Research Funding:** Puma Biotechnology (Inst), Eisai (Inst)

**Susan C. Lester**

**Employment:** Novartis Institutes for BioMedical Research (I), resTORbio (I)

**Leadership:** Blade Therapeutics (I)

**Stock and Other Ownership Interests:** Novartis

**Patents, Royalties, Other Intellectual Property:** More than 20 patents issued and pending related to health care therapies (I)

**Travel, Accommodations, Expenses:** Novartis (I), Blade Therapeutics (I)

**Elizabeth A. Mittendorf**

**Honoraria:** Physician Education Resource

**Consulting or Advisory Role:** Peregrine Pharmaceuticals, TapImmune, Sellas Life Sciences, Merck, Genomic Health

**Research Funding:** Galena Biopharma (Inst), Genentech (Inst), Roche (Inst), AstraZeneca (Inst), EMD Serono (Inst)

No other potential conflicts of interest were reported.

## ACKNOWLEDGMENT

We thank Tari King, MD, for helpful input and the cancer registrars at Brigham and Women's Hospital and Dana-Farber Cancer Institute for invaluable assistance in data acquisition.

## REFERENCES

- Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. *N Engl J Med* 351:2817-2826, 2004
- Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. *J Clin Oncol* 24:3726-3734, 2006
- Albain KS, Barlow WE, Shak S, et al: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. *Lancet Oncol* 11:55-65, 2010
- Dowsett M, Cuzick J, Wale C, et al: Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. *J Clin Oncol* 28:1829-1834, 2010
- National Comprehensive Cancer Network: Breast Cancer, version 1.2018. [https://www.nccn.org/professionals/physician\\_gls/pdf/breast\\_blocks.pdf](https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf)
- Harris LN, Ismaila N, McShane LM, et al: Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 34:1134-1150, 2016
- American Joint Committee on Cancer: AJCC Cancer Staging Manual (ed 8). New York, NY, Springer, 2017
- Sanders MA, Wong SM, Iorgulescu JB, et al: Changes and clarifications in the eighth edition of the AJCC cancer staging system for breast cancer. *AJSP Rev Rep* 23:113-117, 2018

9. Giuliano AE, Connolly JL, Edge SB, et al: Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA Cancer J Clin.* 67:290-303, 2017
10. Sparano JA, Gray RJ, Makower DF, et al: Prospective validation of a 21-gene expression assay in breast cancer. *N Engl J Med* 373:2005-2014, 2015
11. Wong WB, Ramsey SD, Barlow WE, et al: The value of comparative effectiveness research: Projected return on investment of the RxPONDER trial (SWOG S1007). *Contemp Clin Trials* 33:1117-1123, 2012
12. Sparano JA, Gray RJ, Makower DF, et al: Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. *N Engl J Med* 379:111-121, 2018
13. Gluz O, Nitz UA, Christgen M, et al: West German Study Group Phase III PlanB Trial: First prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. *J Clin Oncol* 34:2341-2349, 2016
14. Boffa DJ, Rosen JE, Mallin K, et al: Using the National Cancer Database for outcomes research: A review. *JAMA Oncol* 3:1722-1728, 2017
15. Tavassoli FA, Devilee P (eds): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France, IARC Press, 2003
16. Orucevic A, Bell JL, McNabb AP, et al: Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data. *Breast Cancer Res Treat* 163:51-61, 2017
17. Roberts MC, Miller DP, Shak S, et al: Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX recurrence score results in the SEER database. *Breast Cancer Res Treat* 163:303-310, 2017
18. Bhutiani N, Egger ME, Ajkay N, et al: Multigene signature panels and breast cancer therapy: Patterns of use and impact on clinical decision making. *J Am Coll Surg* 226:406-412.e1, 2018
19. American Joint Committee on Cancer: AJCC Cancer Staging Manual (ed 7). New York, NY, Springer, 2010
20. Commission on Cancer. Facility Oncology Registry Data Standards Manual: 2013 Revision. Chicago, IL, American College of Surgeons, 2013
21. Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *J Clin Epidemiol* 45:613-619, 1992
22. Iorgulescu JB, Harary M, Zogg CK, et al: Improved risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: Results from a national cohort. *Cancer Immunol Res* 6:1039-1045, 2018
23. Cardoso F, van't Veer LJ, Bogaerts J, et al: 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. *N Engl J Med* 375:717-729, 2016

